Article Information
History
- March 26, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Ramzi Ajjan1,
- Elizabeth MA Hensor2,3,
- Kave Shams2,4,
- Francesco Del Galdo2,3,
- Afroze Abbas1,
- Janet Woods5,
- Rebecca J Fairclough6,
- Lorraine Webber7,
- Lindsay Pegg7,
- Adrian Freeman6,
- Ann Morgan1,3,
- Paul M Stewart3,8,
- Angela E Taylor9,
- Wiebke Arlt9,
- Abd Tahrani9,
- David Russell1,5 and
- Ana Tiganescu1,3,*
- 1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
- 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
- 3NIHR Biomedical Research Center, Leeds Teaching Hospitals, NHS Trust, Leeds, UK
- 4Leeds Centre for Dermatology, Chapel Allerton Hospital, Leeds, UK
- 5Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
- 6Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
- 7Emerging portfolio development, Late Oncology, Oncology R&D, AstraZeneca, Cambridge, UK
- 8Faculty of Medicine and Health, University of Leeds, Leeds, UK
- 9Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK; Centre of Endocrinology Diabetes and Metabolism (CEDAM), Birmingham Health partners, Birmingham, UK; Department of Diabetes and Endocrinology, University Hospitals Birmingham NIHS Foundation Trust, Birmingham, UK
- ↵*Corresponding author: Ana Tiganescu, Leeds Institute of Cardiovascular and Metabolic Medicine, School of Medicine, LIGHT Building, Clarendon Way, University of Leeds, LS2 9JT, UK, 0113 34 38336, a.tiganescu{at}leeds.ac.uk
Posted March 26, 2021.
A randomised controlled pilot trial of oral 11β-HSD1 inhibitor AZD4017 for wound healing in adults with type 2 diabetes mellitus
